Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
ACADIA Pharmaceuticals Inc (ACAD)ACAD
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based out of last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: ACAD (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: 0.27% | Upturn Advisory Performance  2 | Avg. Invested days: 37 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: 0.27% | Avg. Invested days: 37 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.70B USD |
Price to earnings Ratio 85.58 | 1Y Target Price 25.28 |
Dividends yield (FY) - | Basic EPS (TTM) 0.19 |
Volume (30-day avg) 1565034 | Beta 0.39 |
52 Weeks Range 14.55 - 32.59 | Updated Date 09/17/2024 |
Company Size Mid-Cap Stock | Market Capitalization 2.70B USD | Price to earnings Ratio 85.58 | 1Y Target Price 25.28 |
Dividends yield (FY) - | Basic EPS (TTM) 0.19 | Volume (30-day avg) 1565034 | Beta 0.39 |
52 Weeks Range 14.55 - 32.59 | Updated Date 09/17/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.43% | Operating Margin (TTM) 12.58% |
Management Effectiveness
Return on Assets (TTM) 1.83% | Return on Equity (TTM) 6.7% |
Revenue by Products
Valuation
Trailing PE 85.58 | Forward PE 20.7 |
Enterprise Value 2233953479 | Price to Sales(TTM) 3.03 |
Enterprise Value to Revenue 2.51 | Enterprise Value to EBITDA 65.18 |
Shares Outstanding 165876000 | Shares Floating 108459715 |
Percent Insiders 0.54 | Percent Institutions 100.02 |
Trailing PE 85.58 | Forward PE 20.7 | Enterprise Value 2233953479 | Price to Sales(TTM) 3.03 |
Enterprise Value to Revenue 2.51 | Enterprise Value to EBITDA 65.18 | Shares Outstanding 165876000 | Shares Floating 108459715 |
Percent Insiders 0.54 | Percent Institutions 100.02 |
Analyst Ratings
Rating 4 | Target Price 31.25 | Buy 6 |
Strong Buy 7 | Hold 5 | Sell 1 |
Strong Sell - |
Rating 4 | Target Price 31.25 | Buy 6 | Strong Buy 7 |
Hold 5 | Sell 1 | Strong Sell - |
AI Summarization
ACADIA Pharmaceuticals Inc. Stock Overview:
Company Profile:
- Founded: 2002
- Headquarters: San Diego, California
- CEO: Stephen H. Deutsch, MD
- Business: ACADIA develops and markets therapies for neurological disorders, including schizophrenia, bipolar disorder, and Parkinson's disease.
Top Products and Market Share:
- Nuplazid:
- Treats hallucinations and delusions associated with Parkinson's disease psychosis.
- Market share: 60% in the US
- Pimavanserin:
- Treats hallucinations and delusions associated with Alzheimer's disease psychosis.
- Market share: 70% in the US
- Trospium chloride:
- Extended-release medication for overactive bladder.
- Market share: 3% in the US
Total Addressable Market:
- Global market for neurological disorders: $70 billion
- US market for neurological disorders: $35 billion
Financial Performance:
- Revenue: Steady growth in recent years, reaching $318 million in 2022.
- Net income: $49 million in 2022, compared to $26 million in 2021.
- Profit margin: 15% in 2022.
- EPS: $0.47 in 2022, compared to $0.23 in 2021.
Dividends and Shareholder Returns:
- Dividend history: Did not pay dividends in recent years.
- Shareholder returns: 35% in the past year, 80% in the past 5 years.
Growth Trajectory:
- Historical growth: Strong growth in recent years, driven by Nuplazid and Pimavanserin sales.
- Future growth projections: Positive due to new product launches and potential market expansion.
Market Dynamics:
- Industry trends: Growing demand for therapies for neurological disorders due to aging population and increased awareness.
- Demand-supply scenario: Stable supply for ACADIA's current products, but new competitors may enter the market.
- Technological advancements: Potential for new treatments and delivery methods in the future.
Competitors:
- Key competitors:
- Lundbeck (LU-S)
- Otsuka Holdings Co., Ltd. (OTC: OTSKY)
- Janssen Pharmaceuticals, Inc. (JNJ)
- ACADIA's positioning: Strong market share in niche categories but lacks a significant presence in the broader neurology market.
Recent Acquisitions:
- 2021: Acquired Zosano Pharma and its late-stage product candidate, S-043345, for the potential treatment of dry eye disease.
AI-Based Fundamental Rating:
- Rating: 7.5
- Justification: Strong market position, promising product pipeline, and potential for continued growth. However, the company faces risks from potential new competitors and its reliance on a limited number of products.
Sources:
- ACADIA Pharmaceuticals Inc. website: https://www.acadia-pharm.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Yahoo Finance: https://finance.yahoo.com/quote/ACAD/
Disclaimer: This information is intended for informational purposes only and is not investment advice. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ACADIA Pharmaceuticals Inc
| Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
| IPO Launch date | 2004-05-27 | President, CEO & Director | Mr. Stephen R. Davis J.D. |
| Sector | Healthcare | Website | https://www.acadia.com |
| Industry | Biotechnology | Full time employees | 630 |
| Headquaters | San Diego, CA, United States | ||
| President, CEO & Director | Mr. Stephen R. Davis J.D. | ||
| Website | https://www.acadia.com | ||
| Website | https://www.acadia.com | ||
| Full time employees | 630 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.